(Q30352329)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Jean Haensler

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

1 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Vaccines

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

747-758

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

THE STERILIZATION OF LIPOVACCINES.

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Freund's complete and incomplete adjuvants, preparation, and quality control standards for experimental laboratory animals use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Syntex adjuvant formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Squalene emulsions for parenteral vaccine and drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

The mechanism of action of MF59 - an innately attractive adjuvant formulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

The history of MF59(®) adjuvant: a phoenix that arose from the ashes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Aflunov(®): a prepandemic influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 month

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Vaccinate before the next pandemic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

MF59 adjuvant: the best insurance against influenza strain diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Protective effect of single-dose adjuvanted pandemic influenza vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Vaccine prevention of maternal cytomegalovirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-gamma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a phase 1 randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a phase 1 randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

A field trial to assess a blood-stage malaria vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

The RTS,S vaccine candidate for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Improved CD4⁺ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

21 January 2018

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

New adjuvanted vaccines in pregnancy: what is known about their safety?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Exposure to MF59-adjuvanted influenza vaccines during pregnancy--a retrospective analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Guillain-Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case-control study in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Association between Guillain-Barré syndrome and influenza A (H1N1) 2009 monovalent inactivated vaccines in the USA: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Implications of narcolepsy link with swine-influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Outlining novel cellular adjuvant products for therapeutic vaccines against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Stable isotope ratios of carbon and hydrogen to distinguish olive oil from shark squalene-squalane

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Formulated squalene for food related applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Adjuvants designed for veterinary and human vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Association of a polymorphism of BTN2A1 with chronic kidney disease in individuals with or without hypertension or diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.2013.811188

10.1586/14760584.2013.811188

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23885820%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference